APA (7th ed.) Citation

G, J., G, C., M, L., F, R., R, C., E, L. P., . . . A, K. (2024). High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS. JAMA neurology, 81(5), 490. https://doi.org/10.1001/jamaneurol.2024.0395

Chicago Style (17th ed.) Citation

G, Jouvenot, et al. "High-Efficacy Therapy Discontinuation Vs Continuation in Patients 50 Years and Older With Nonactive MS." JAMA Neurology 81, no. 5 (2024): 490. https://doi.org/10.1001/jamaneurol.2024.0395.

MLA (9th ed.) Citation

G, Jouvenot, et al. "High-Efficacy Therapy Discontinuation Vs Continuation in Patients 50 Years and Older With Nonactive MS." JAMA Neurology, vol. 81, no. 5, 2024, p. 490, https://doi.org/10.1001/jamaneurol.2024.0395.